一品红 (300723.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−116.9x

Market Cap

CNY 15.63B

MomentumView details →

1D Return

−5.82%

YTD Return

+6.08%

RSI (14)

45.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−116.9x

Market Cap

CNY 15.63B

RSI (14)

45.4

MomentumView details →

1D Return

−5.82%

YTD Return

+6.08%

ProfitabilityView details →

Gross Margin

58.58%

Net Margin

21.26%

EBITDA Margin

−15.24%

ROE (TTM)

10.33%

ROA (TTM)

4.26%

Asset Turnover

0.22x

GrowthView details →

Revenue YoY

−21.88%

EPS YoY

+134.25%

FCF YoY

+89.57%

Revenue CAGR 3Y

−25.78%

EPS CAGR 3Y

+37.45%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−CNY 0.24

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

1.04x

Current Ratio

1.45x

Quick Ratio

1.30x

Div Yield

—

Div Rate

—

Div Growth 1Y

+5.00%

Financials snapshotView financials →

Revenue (TTM)

940.78M

Net Income (TTM)

199.99M

Op. CF (TTM)

26.38M

Next earningsOct 16, 2026 →

Latest newsMore news →

Yipinhong announced that its gout innovative drug AR882 (deupirtenone) capsules met the primary endpoint in a Phase III clinical trial for treating gout with hyperuricemia, showing significant efficacy and good safety.2d ago

Yipinhong's wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its self-developed innovative drug APH03867 tablets, intended for treating gout with hyperuricemia.15d ago

Similar companies

深天马Ａ000050.SZ 老板电器002508.SZ 麦捷科技300319.SZ 江特电机002176.SZ 怡合达301029.SZ 森马服饰002563.SZ Find similar companies →

Latest newsMore news →

Yipinhong announced that its gout innovative drug AR882 (deupirtenone) capsules met the primary endpoint in a Phase III clinical trial for treating gout with hyperuricemia, showing significant efficacy and good safety.2d ago Yipinhong's wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its self-developed innovative drug APH03867 tablets, intended for treating gout with hyperuricemia.15d ago Yipinhong's subsidiary Guangzhou Yipinhong Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its innovative drug APH04935, a small-molecule GLP-1R agonist for weight control.19d ago